Condition 1: Hormonal status in patients with polycystic ovary syndrome. Condition 2: Status of inflammatory factors in patients with polycystic ovary syndrome. Polycystic ovarian syndrome Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Treatment with 500 mg apple cider vinegar capsules. Intervention 2: Control group: Treatment with apple cider vinegar placebo.
Sponsors
Tarbiat Modares University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Diagnosis of polycystic ovary syndrome based on the 2003 Rotterdam criteria. Iranian nationality (based on statements from the research unit) Not pregnant (based on the research unit's statements) Be literate. Be willing to participate in the study. Absence of chronic diseases affecting PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, thyroid dysfunction) (based on statements from the research unit and the patient's health record) No smoking or alcohol consumption Age 18 to 40 years
Exclusion criteria
Exclusion criteria: People who experience medication side effects. Unwillingness to continue participating in the study and non-compliance with the treatment protocol (less than 80% of the prescribed apple cider vinegar during the treatment period (less than 201 capsules over a 3-month period) (49)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: use of scales.;Blood levels of anti-Mullerian hormone. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Blood biochemical test.;Blood levels of luteinizing hormone. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Blood biochemical test.;Serum levels of follicle-stimulating hormone. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Blood biochemical test.;Serum C-reactive protein level. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Blood biochemical test.;Hirsutism. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Patient statements and clinical symptoms.;Quality of life. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Patient statements.;Waist-to-hip ratio. Timepoint: At the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: use of meter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Menstrual disorders including amenorrhea and oligomenorrhea. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Patient statements.;Hirsutism. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Patient statements.;Sexual function. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Patient statements.;Quality of life. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Patient statements.;Interleukin 6 blood level. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Blood biochemical test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahideh Jahanian Sadatmahalleh
Tarbiat Modares University
Outcome results
None listed